Updated 8/8/2011 7:15 p.m.
Oncology
Greener pastures lure Delcath and Osteologix
Cardiac medical device firm Sunshine Heart raises $4.6 million | Funding Roundup
Cardiac medical device firm Sunshine Heart (ASX:SHC) raised $4.6 million by selling 115 million shares in a private placement with institutional investors in the U.S. and Canada at 4 cents per share.
The Eden Prairie, Minnesota-based company is developing the C-Pulse(R) Heart Assist System, an implantable, non-blood-contacting, heart assist therapy to treat moderate to severe heart failure.
Neoprobe: Does stock’s 40 percent drop validate its biggest critic?
The hedge fund manager Neoprobe Corp. (NYSE Amex:NEOP) investors love to hate isn’t eager to take credit for the cancer diagnostics company’s free-falling stock price.
Treatment abandonment in childhood cancer: Are we willing to face this challenge?
Neoprobe launches European branch amid U.S. boondoggle
Cancer diagnostics company Neoprobe Corp. (NYSE Amex:NEOP) announced today that it established a European business unit tasked with development and commercialization in the European Union.
The move underscores the Dublin, Ohio-based company’s focus on international commercialization of its flagship Lymphoseek radiopharmaceutical, a diagnostic tracing agent for detecting and treating certain types of cancer.
Girls rocking science
My daughter begged me not to sign her up for her school’s LEGO League (a robotics program designed to ignite kids’ interest in science and technology) — among other reasons, because most of the participants are boys. Being that she was only in first grade, I let it drop.
Delcath shares slip 10% on announcement of 5 million shares of common stock for sale
Shares of Delcath Systems Inc. (NSDQ:DCTH) slid 10 percent on Wall Street during mid-day trading on news that the company plans to sell 5 million shares of its common stock through Jefferies & Company Inc., which will act as bookrunner and solicit investors to subscribe.
DCTH shares slipped to $5.28 in mid-day trading today, down 10 percent from yesterday’s closing price of $5.87.
World’s first synthetic organ transplant saves man from cancer
MASSDEVICE ON CALL —Doctors at Sweden’s Karolinska University hospital implanted the world’s first fully synthetic organ into a patient last month, effectively ridding the man of the cancer that threatened his life.
The 36-year-old male patient received a trachea made of his own stem cells, doing away with the risk of rejection or the need for a lifetime of immunosuppressive drugs.
MassDevice Q&A: Delcath CEO Eamonn Hobbs
Delcath Systems Inc. (NSDQ:DCTH) CEO Eamonn Hobbs is in a good mood these days.
Neoprobe officially rebuts Lymphoseek trial critics
Neoprobe Corp. (NYSE:NEOP) filed a formal response to a challenge to a pending FDA application for its flagship Lymphoseek compound, calling the citizen’s petition "inaccurate" and "misleading."
Last week, MSMB Capital Management submitted the petition asking the FDA to block Neoprobe’s application on the grounds that the drug’s pivotal trials suffered from vital mistakes. The allegations included charges that the trials are not adequately controlled and contain conflicts of interest that may have compromised their integrity.